Traditional bioconjugate development required an extensive network of partners often spread across different site. However, our “All-in-One” facilities operational in the Wuxi city site has encompassed mAb intermediates, payload-linker, as well as ADC DS and DP, the entire ADC supply chain within one single site. Our "All-in-One" manufacturing strategy simplifies the entire process, offering significant advantages for your bioconjugate projects: 🛡 Lowered Risks 💰 Reduced Costs ⏱️ Accelerated Timelines Connect to our experts today: https://lnkd.in/eCgHTVqf #bioconjugation #biomanufacturing #biopharma #biologics #biotherapeutics #ADC #antibodydrugconjugate
WuXi Biologics
Pharmaceutical Manufacturing
Wuxi, Jiangsu 96,351 followers
A true global single-source drug development technology platform from concept to commercialization.
About us
Our Vision: “Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S., China, Ireland, Germany, and Singapore exceeding 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.
- Website
-
https://www.wuxibiologics.com/
External link for WuXi Biologics
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Wuxi, Jiangsu
- Type
- Public Company
- Founded
- 2010
- Specialties
- Biologics conjugation, Bioprocess CMC, Biosafety, Biologics GMP Manufacturing, Biologics discovery service, Cell Line Development, Formulation Development, Analytical Characterization, Cell Culture and Purification Process Development, Monoclonal Antibodies (mAbs), vaccine development, vaccine manufacturing, antibody discovery, antibody manufacturing, protein production, analytical services, biotherapeutics, biopharmaceuticals, and continuous manufacturing
Locations
Employees at WuXi Biologics
Updates
-
High concentration = higher patient compliance🎧 Tune into this podcast with Dr. Guo and Cell Culture Dish as they explore breakthroughs in high-concentration formulations for chronic diseases cancer, rheumatoid arthritis, and more. Discover how WuXi Biologics uses advanced technologies like WuXiHigh™ to tackle challenges and deliver stable, effective formulations for prefilled syringes and autoinjectors. Catch the recording here https://lnkd.in/gtShVy_S. #DrugDevelopment #Biologics #HealthcareTechnology #Podcast #ChronicDiseases #HealthcareInnovation #PatientCompliance
-
Cutting-edge technology doesn’t have to come with a high price tag. 🔬💡 Our established processes unite innovation and manufacturing excellence to increase productivity while reducing the cost of goods sold (COGS). Boost your bottom line without sacrificing quality—let us show you how! 🐾💰 Learn more: https://lnkd.in/eiUh6MzQ #AnimalHealth #CostEfficiency #Innovation #Manufacturing #Productivity
-
-
Facility Spotlight: Let us help you realize your breakthrough biological treatment from concept to clinical trials and beyond, discovered, developed and manufactured here in the United States. Here’s a quick glimpse of our U.S.-based facilities and high-quality CMC development capabilities and services for biologics (e.g., monoclonal and bispecific antibodies, antibody drug conjugates, recombinant proteins and vaccines). https://lnkd.in/eyBYfwq8 #cmcdevelopment #biomanufacturing #drugdevelopment #biologics
U.S. Based Facilities, Services and Operations – Development Video
https://www.youtube.com/
-
Register today for "Achieving High Titer & Superior Purity Across Diverse Bispecific Antibody Formats" Bispecific antibodies (BsAbs) are at the forefront of therapeutic innovation, but their production is often hindered by challenges such as low titers and difficult-to-remove impurities like homodimers and mispaired species. Additionally, each BsAb format presents unique complexities in the production process. This webinar will showcase innovative solutions to these challenges, including ultra-high-titer CHO expression systems, optimized chain ratios, and Intact Mass-assisted purification processes tailored for various formats like CrossMab, WuXiBody, and others. Through detailed case studies, we will demonstrate how these approaches consistently achieve over 98% heterodimer purity and endotoxin levels below 0.1 EU/mg. During the webinar, you will gain valuable insight into: • Innovative strategies to overcome low titers, mispaired species and homodimers. • Advanced chain ratio optimization for formats like CrossMab and WuXiBody, improving expression and titer. • Case studies illustrating Intact Mass-assisted purification tailored for various formats, such as CrossMab, WuXiBody, and ScFv-Fab, consistently achieving heterodimer purity >98% and endotoxin levels <0.1 EU/mg. Register today: https://lnkd.in/gcTyUHDD #BispecificAntibodies #BiotechWebinar #AntibodyTherapy #ProteinEngineering #BiotechInnovation #AntibodyProduction #DrugDevelopment
-
-
From October 9-11, BioJapan 2024 at PACIFICO Yokohama brought together leaders in biotech and pharma industry, and we were thrilled to be a part of it. Jimmy Li’s insightful presentation on accelerating ADC CMC development with WuXi XDC’s CRDMO services sparked great interest and positive feedback. At WuXi Biologics, Booth D35, we were excited to connect with both familiar faces and new partners, all in the spirit of advancing biotech for better patient outcomes. A heartfelt thank you to everyone who joined us – together, we’ll continue driving innovation in biotechnology. #BioJapan2024 #BiotechInnovation #PharmaIndustry #CRDMO #PacificoYokohama #BiotechNetworking #BiotechCommunity
-
-
The WuXiHigh™ platform, is a proprietary and revolutionary high concentration (up to 200 mg/mL) biopharmaceutical development platform, incorporating features such as novel methodology in viscosity reduction, synergistic excipient combinations, computer-assisted formulation development and high-throughput formulation screening strategies. The platform offers innovative solutions for our clients and the platform can be tailored for various biopharmaceuticals, including monoclonal antibodies (mAb), bispecific antibodies (BsAb), fusion proteins and other types of biologics. Learn more: https://lnkd.in/dFgcVqGc #drugproducts #drugformulation #drugproductdevelopment
-
-
WuXi Biologics offers extensive and integrated Preclinical Candidates (PCC) screening studies in the evaluation and selection of lead mAb (or other biologics) therapeutic candidates. Preclinical assessment is just one part of our wide-ranging antibody discovery services. Let's get started. https://lnkd.in/e4sVN6wF #biologics #antibodydisocovery #biotherapeutics #biopharma #drugdevelopment
-
-
Will you be attending PEGS Europe (November 5-7) in Barcelona, Spain? Our WuXi Biologics team will be available to discuss your R&D and drug discovery goals during the event. Contact us and we'll set up a convenient time to discuss your outsourcing or partnering needs. Request a meeting: https://lnkd.in/gvNFGynY #PEGS #Europe #BarcelonaEvents #BiotechConference #DrugDiscovery #R&DGoals #Outsourcing #PharmaPartnerships
-
-
Stay at the forefront of biologics discovery and development with WuXi Biologics’ CRO Services! From antibody discovery to R&D protein production, we support your biologics development at every stage. Follow us for access to expert-led webinars, in-depth case studies, cutting-edge industry articles, and the latest technologies—all in one place! Explore Now: https://lnkd.in/ea4242aa
-